FRLN News and Press, Freeline Therapeutics Holdings plc From 05/10/22

Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership team LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holding...

LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25 th Annual Meeting of the American Society of Gene and Cell Therapy (AS...

Freeline Therapeutics (NASDAQ:FRLN) appointed Paul M. Schneider as its CFO, effective May 16. Most recently, he served as SVP, Finance and Operations at Exo Therapeutics. His experience in early-stage drug development will provide discipline and focus to the company's R&D strate...

LONDON, April 19, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that Paul M. Schneider has been appointed Chief Financial Officer (CFO), effective May 16, 2022, based in Boston. Mr. Schnei...

Freeline Therapeutics press release (NASDAQ:FRLN): FY GAAP EPS of -$3.93. Cash and cash equivalents of $117.67m For further details see: Freeline Therapeutics GAAP EPS of -$3.93

Phase 1/2 programs on track in Hemophilia B and Gaucher disease and accelerated in Fabry disease Extended financial runway and streamlined organization support Company through key data readouts across all three clinical programs Strengthened leadership team with ap...

Plantronics POLY +49% HP to acquire Poly for $40/share for enhancing Peripherals and workforce solutions businesses. Kaixin Auto KXIN +42% on intention order for 20K electric vehicles. DatChat (DATS) +34% to launch metaverse advertising and NFT monetization platform. ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! It’s time to start off the week with an overview of the biggest pre-market stock movers for Monday! Source: f11photo/Shutterstock.com A reverse stock split, earnings, FDA approval, and m...

Freeline Therapeutics (NASDAQ:FRLN) has added ~17% in the post-market Friday on the news that Guernsey-based investment firm Syncona Limited has a ~63% stake in the clinical-stage biotechnology company. Syncona has revealed the position through a 13-D filing submitted to t...

Company to progress to second dose cohort in the MARVEL-1 study immediately, with first patient dosing expected in mid-2022 LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”...